Faberco assures access to COVID-19 drug Molnupiravir

Pharmaceutical firm Faberco Life Sciences Inc. (Faberco) assured that the country will have enough supply of oral antiviral drug Molnupiravir amid the rise in coronavirus disease (COVID-19) infections.

“Faberco Life Sciences is committed to address the urgent need for Molnupiravir and ensure to allocate enough supply to respond the surging need in the coming days,” it said in a statement.

The firm said that “several local government units, hospitals, and other health facilities have been served with Molnupiravir.”

On Dec. 22, the country's Food and Drug Administration (FDA) has approved the emergency use of Molnupiravir under the brand name Molnarz for "treatment of mild to moderate” COVID-19 in individuals 18 years old and above.

Faberco was appointed to distribute Molnupiravir in the country by Aurobindo Pharma Ltd., a partner manufacturer of Merck & Co, the developer of this COVID-19 pill.